These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 17551298

  • 1. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
    Chiappino I, Destefanis P, Addeo A, Galetto A, Cucchiarale G, Munoz F, Zitella A, Ferrando U, Fontana D, Ricardi U, Tizzani A, Bertetto O.
    Am J Clin Oncol; 2007 Jun; 30(3):234-8. PubMed ID: 17551298
    [Abstract] [Full Text] [Related]

  • 2. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
    Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J, Muggia F.
    Cancer; 2001 Jun 01; 91(11):2039-45. PubMed ID: 11391583
    [Abstract] [Full Text] [Related]

  • 3. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM.
    Cancer; 2007 Sep 01; 110(5):996-1002. PubMed ID: 17639587
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.
    Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR.
    Cancer; 2004 Nov 01; 101(9):2034-41. PubMed ID: 15455357
    [Abstract] [Full Text] [Related]

  • 5. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
    Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, McAleer C.
    Semin Oncol; 1995 Oct 01; 22(5 Suppl 12):41-5. PubMed ID: 7481860
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ.
    Cancer; 2003 Jul 15; 98(2):269-76. PubMed ID: 12872344
    [Abstract] [Full Text] [Related]

  • 7. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
    Athanasiadis A, Tsavdaridis D, Rigatos SK, Athanasiadis I, Pergantas N, Stathopoulos GP.
    Anticancer Res; 2003 Jul 15; 23(3C):3085-8. PubMed ID: 12926166
    [Abstract] [Full Text] [Related]

  • 8. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
    Meluch AA, Greco FA, Morrissey LH, Raefsky EL, Steis RG, Butts JA, Hainsworth JD, Minnie Pearl Cancer Research Network.
    Cancer; 2003 Nov 15; 98(10):2192-8. PubMed ID: 14601089
    [Abstract] [Full Text] [Related]

  • 9. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
    Amato RJ, Hernandez-McClain J, Henary H.
    Am J Clin Oncol; 2008 Dec 15; 31(6):532-8. PubMed ID: 19060583
    [Abstract] [Full Text] [Related]

  • 10. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
    Hussain M, Tangen CM, Lara PN, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED, Southwest Oncology Group.
    J Clin Oncol; 2005 Dec 01; 23(34):8724-9. PubMed ID: 16314632
    [Abstract] [Full Text] [Related]

  • 11. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
    Ansari MS, Gupta NP.
    Urol Oncol; 2004 Dec 01; 22(5):415-20. PubMed ID: 15464923
    [Abstract] [Full Text] [Related]

  • 12. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
    Amato RJ, Sarao H.
    Clin Genitourin Cancer; 2006 Mar 01; 4(4):281-6. PubMed ID: 16729912
    [Abstract] [Full Text] [Related]

  • 13. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
    Vaughn DJ, Brown AW, Harker WG, Huh S, Miller L, Rinaldi D, Kabbinavar F.
    Cancer; 2004 Feb 15; 100(4):746-50. PubMed ID: 14770430
    [Abstract] [Full Text] [Related]

  • 14. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G.
    Clin Lung Cancer; 2008 Sep 15; 9(5):280-4. PubMed ID: 18824450
    [Abstract] [Full Text] [Related]

  • 15. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y, Shu Y, Xu Q.
    Biomed Pharmacother; 2009 May 15; 63(4):293-6. PubMed ID: 18848761
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI.
    Oncol Rep; 2009 Feb 15; 21(2):523-9. PubMed ID: 19148531
    [Abstract] [Full Text] [Related]

  • 17. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.
    Lin CC, Hsu CH, Hour TC, Cheng AL, Huang CY, Huang KH, Chen J, Pu YS.
    Urol Oncol; 2007 Feb 15; 25(3):207-13. PubMed ID: 17483017
    [Abstract] [Full Text] [Related]

  • 18. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study).
    Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N, Chubu Clinical Cancer Group.
    Anticancer Res; 2007 Feb 15; 27(4C):2667-71. PubMed ID: 17695430
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
    Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A.
    Cancer Invest; 2005 Feb 15; 23(1):13-8. PubMed ID: 15779863
    [Abstract] [Full Text] [Related]

  • 20. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
    Ferrero JM, Foa C, Thezenas S, Ronchin P, Peyrade F, Valenza B, Lesbats G, Garnier G, Boublil JL, Tchiknavorian X, Chevallier D, Amiel J.
    Oncology; 2004 Feb 15; 66(4):281-7. PubMed ID: 15218295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.